Sign inJoin free

Watch / Three stocks for...

Three ‘resilient’ stocks with upside

26 June 20247:02

Three ‘resilient’ stocks with upside

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Marc Whittaker of Investors Mutual delves into the potential of various companies active in the Australian market. He initially addresses Collins Foods (ASX:CKF), applauding the company's noted resilience which has been exemplified in its performance featuring the iconic KFC brand. Despite concerns over the brand's margins in the first half of the ongoing financial year, Marc remains optimistic for their outlook, stating Collins Foods (ASX:CKF) is in a well-placed position for future growth.

Shifting his focus to elements of the dairy industry, Marc looks at Bega Cheese (ASX:BGA) specifically. He notes the promising rise in share prices, assigning this movement to the lowering price they pay to procure milk, making their bulk business suddenly profitable. He elaborates, confident that the company is benefiting from a 'trading down' price trend amongst consumers who are now selecting less expensive, but still high-quality dairy options. Marc finishes his thoughts on Bega Cheese (ASX:BGA) with an enthusiastic insight on its continued growth potential.

Lastly, the Australian Clinical Labs (ASX:ACL) come under scrutiny where Marc discusses the comparison between them and Helius Laboratories. Marc comments on the impressive growth ACL is experiencing due to its smart investments in laboratory technology and systems, proving double the margins Helius reports. He disavows concerns generated by Helius’ performance, emphasising that ACL is significantly outperforming its competitors in the sector

Full unedited transcript below:

0:00

Let's get further into the small end of the market. My next guest is putting the focus on Collins Foods. Yep, check Bega Cheese and Australian Clinical Labs. Maybe there's an update there. Mark Whittaker from Investors Mutual joins me to discuss. Hey Mark. Nice to see you. Dean, how are you? I'm glad you're here to discuss Collins food. My guess. Oh. I'm glad. Well, I'm glad you're glad. Um, are you going out and buying KFC? Are you doing it more as your purse strings become tighter? Well, this is an interesting, uh, I guess, stock to talk about. Obviously, the result yesterday, which was well received on the day. It's off a little bit this morning. But I think generally the resilience of that particular performance was what caught my eye. And in all three stocks that I'm talking about with you today, I think the keyword here is resilient. So we want to talk about the CPI print at 11:30. Resilience might be an issue that investors might want to be aware of and target when they're looking at stocks. I think Collins Food, with that iconic KFC brand that it's a very powerful brand in that QSR quick service restaurant space. I've got six kids in the Deen. People

1:00

might not know that, but when I take on the carrier so I can get to, I can feed the family for about $35. So everyone gets a feed that includes two teenagers, right? So, you know, people are hungry. We can feed them for $35. I get their server protein, they're happy they're full. That's quite an attractive sort of deal for for a large family, a small family. Things are getting tight, people trading down. I think the KFC is an ultimate brand to to benefit from that. There is concern about their margins in the first half of the current financial year for them. But I think longer term, you look at the second half of 25, they are actually cycling some pretty strong comps in the first half of last year. I think that margin expansion, which we saw in the result yesterday, maybe under a little bit of pressure in the first half, but I think that expands again in the second half. So I think that company is really well placed, but surely it's very strong optionality around rolling out new stores, growing further offshore. And that KFC brand is still powerful. I think there's value in the menu when you go into the store and there's value in the share price, so I think it's a very for me, it's a very strong combination. You're not worried about the overseas business? No. Look, I think as I say, I think

1:59

KFC is a powerful brand globally. So when you look at the QSR, how QSR trades in times of economic, I guess tightness, it does tend to outperform. And I think is one of those core brands it will tend to outperform. Um, there are some pressures offshore as well. Yes, I can say that. But short term I think medium term, longer term this is this looks like a pretty compelling proposition to me. Okay. So we're talking resilience. We are indeed. And so Bega Cheese I guess we just call it Bega because it's Vegemite. It's peanut butter. It's bigger peanut butter. It's your play. It's Yoplait, it's dairy farmers. It's farmers union for South Australia. Don't drink anything else but farmers union. And it's getting into like the alternative almond and soy. Yeah. They're iced coffee which there's a bit of new product innovation in their dairy iced coffee brand, which is a very powerful and very leading brand in in the consumer channel. It's interesting. I hadn't actually realised that its share price had improved that much over the I like that share price chart. That looks quite. Can it keep going? It's actually had a rally of late. There's a couple of reasons for that. Let me let me take you through

2:59

them quickly. Firstly the farmgate milk price or the price they they pay to procure milk, particularly in Victoria, is likely to be about $8 or the low $8 range per per kilo of milk solids. It's been above $9 last year, so that price is coming right in. So all of a sudden their bulk business, their commodity business, which really I guess where's the slings and arrows of that milk price that's been losing money. So it lost about $20 million last year. All of a sudden if we get that milk price at about $8, $8.20 or thereabouts, that division is going to be making about $20 million. So there's a $40 million swing in EBITDA just there. So that's quite powerful. The industry is rationalising. So we've got the likes of Lactalis, Saputo, Fonterra, either selling assets, divesting assets, closing assets, um, buying less milk. So that puts less pressure on that milk price. So that's actually quite a positive benefit for Baker, who buys about 1.3 billion litres of milk a year. So it's a it's a big cost of goods sold I think. Secondly, those brands that we talked about in that consumer channel, in grocery in particular, they're benefiting from trading down.

3:59

So you might have bought, you know, the XYZ co-op dairy milk brand at $8 a litre. When you're feeling good about yourself, all of a sudden, you know, dairy farmers at 50 for a litre must not be that bad. So I think they're benefiting from that trade down in the likes of Coles, Woolworths, Aldi and so forth. And those bands are all those brands are all powerful. It's only trading on ten times EBITDA, which puts it at a significant discount to its global PS in that branded consumer space, in that food space. I'm not saying that it's the same quality as necessarily some of those offshore peers, but at ten times I think that the valuation looks quite attractive. It's got growth in front of it. Again, options, balance sheets. The gearing is going to give the company options to grow further over the next 2 to 3 years. And the milk price outlook, which is a lot more benign. I think that's that's quite a positive combination for that particular company as well. Okay. So more upside in the share price I think. So. Um, and then Australian clinical Labs, were you not spooked by Helius yesterday? I want to draw I want to compare and contrast. That's my my my highlighting ACL to you. So if you look at the Helius result

4:58

yesterday. Revenues aren't a problem. Volume is another problem. Where their problem lies is in their margins. So if I look at their release yesterday, it looks like their Ebit margins are about 4 to 5%. If you compare that to ICL, which is again experiencing good growth in volumes. So they're growing at 5 to 6% top line. And that's all volume growth right. There's no indexation. There's no there's no government money on top of that coming in. So they're growing literally at 5 or 6% top line. Their revenues are growing at 5 to 6%. Their margins are closer to 10%. So more than double the margins that really is are reporting. And the reason for that is that if we go back through 4 or 5 years, ACL is actually invested into their laboratory technology, their systems, their ability to manage their workflows across the different laboratories. Helios hasn't done that. So Helios downgrade yesterday almost proved up your thesis that you've had for a long time when it comes to ACL, compared to in terms of efficiency, ability to manage workflows, utilization of their fixed cost laboratory laboratories, which is all important in pathology. I see I'll just leave

5:58

Helius in the shade and that's really the highlight. The difference I want to highlight. So people look at Helios and they go, oh, the sector is in trouble. Let's drag the whole sector down. No, that's not that's not the case. ACL is actually outperforming quite significantly. Cool. All right. So we've already got the earnings result from Collins Food at B. Yeah. And that was one that I think you could sleep at night beforehand. So now can you sleep at night for ACL and Bega ahead of earnings. Well bigger I think the numbers for this year are very much locked in. And I think the numbers for next year, they're very they're very emphatic on a number for next year. But I think they can beat that number okay. About 190 EBITDA for FY 25. So I think just given the tailwinds that we're seeing consumers trading down, the lack of or the lesser competitive intensity in the sector as well, I think that's all to the to the betterment and pathology volumes are improving. I think May was a little bit soft, but if you look at the three month rolling average and the the last 12 months, pathology volumes have returned to what they should be mid-cycle 5 to 6%. They've got that margin benefit, they've got that investment benefit. They've got that operating leverage, which is what Helios doesn't have. It's all

6:58

about operating leverage. And that's coming through in the ACL numbers.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy